http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019247228-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_504ec79e252dc92db7b47b042e354ff4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-0017 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6927 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13 |
| filingDate | 2019-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5c4f2c84111a41f272e119cbf22fa8d |
| publicationDate | 2019-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2019247228-A1 |
| titleOfInvention | Ophthalmic Drug Delivery Method |
| abstract | A method of treatment is disclosed herein. The method includes administering to a patient in need thereof a polymer implant device containing a biocompatible drug, or a plurality of nanoparticles or microparticles conjugated with the biocompatible drug, the biocompatible drug comprising one or more Rock inhibitors, one or more Wnt inhibitors, one or more integrin inhibitors, and/or one or more glycogen synthase kinase 3 (GSK-3) inhibitors, the patient having a medical condition selected from the group consisting of dry eye, glaucoma, retinal detachment, retinal degeneration, age-related macular degeneration, a cataract, uveitis, a corneal genetic disease, postoperative inflammation, immune-related inflammatory processes, diabetic retinopathy, a side effect occurring after cataract surgery, a side effect occurring after refractive surgery, and combinations thereof. The administration of the biocompatible drug to the patient treats the medical condition, reduces the symptoms associated with the medical condition, enhances nerve regeneration, and/or alleviates the medical condition. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112915213-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113288889-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112451676-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020345805-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022273583-A1 |
| priorityDate | 2008-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 238.